A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

459

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus, CKD and Albuminuria

Interventions

DRUG: Dapagliflozin 10 mg
DRUG: Saxagliptin 2.5 mg
DRUG: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

Sponsor

AstraZeneca